Potential Benefits of Expanded Palivizumab in American Indian Children Under the Age of 2 Years-Reference-Cited by-同舟云学术

Potential Benefits of Expanded Palivizumab in American Indian Children Under the Age of 2 Years

Published:2023-09-01 Issue:9 Volume:12 Page:522-524
ISSN:2048-7207
Container-title:Journal of the Pediatric Infectious Diseases Society
language:en
Short-container-title:

Author:

Close Ryan M¹^ORCID,Palmer Alvin S¹,McAuley James B¹

Affiliation:

1. Whiteriver Service Unit, Indian Health Service , Whiteriver, Arizona , USA

Abstract

Abstract Severe respiratory syncytial virus (RSV) infections disparately impact American Indian communities. We implemented a program that expanded palivizumab to all children under 2 years of age that led to significant reductions in RSV infections and hospitalizations for both high-risk and non-high-risk recipients in a rural American Indian community in Eastern Arizona.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,General Medicine,Pediatrics, Perinatology and Child Health

Link

https://academic.oup.com/jpids/advance-article-pdf/doi/10.1093/jpids/piad063/51516962/piad063.pdf

Reference8 articles.

1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis;Li;Lancet,2022

2. RSV among American Indian and Alaska native children: 2019 to 2020;Atwell;Pediatrics,2023

3. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection;Brady;Pediatrics,2014

4. Updated guidance: use of palivizumab prophylaxis to prevent hospitalization from severe respiratory syncytial virus infection during the 2022-2023 RSV season;Committee on Infectious Diseases and Bronchiolitis Guidelines Committee,2022

5. Respiratory syncytial virus infection in Navajo and White Mountain Apache children;Bockova;Pediatrics,2002